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Abstract  
Total tau protein (t-tau) levels in cerebrospinal fluid (CSF) (CSF-tau) are markedly 
elevated in patients with Creutzfeldt-Jakob disease (CJD).  Some CSF-tau may leak into 
the blood.  We evaluated t-tau levels in serum (serum-tau) as a possible marker for the 
differential diagnosis of CJD from Alzheimer’s disease (AD) and other rapidly 
progressive dementias (RPD).  Serum- and CSF-tau levels were determined in patients 
with sporadic CJD (n = 12), AD (n = 10) and RPD but no CJD (non-CJD-RPD; n =9) 
who showed RPD fulfilling the WHO criteria for possible CJD at onset and had a final 
diagnosis other than CJD.  We also analyzed serum-tau levels in healthy volunteers as a 
control group (n = 10).  Serum- as well as CSF-tau levels were significantly elevated in 
CJD group compared to those in AD, non-CJD-RPD and healthy control groups.  Serum-
tau would be a simple and useful marker to distinguish CJD from AD and non-CJD-RPD, 
requiring further large study to confirm this.   
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Introduction 
Cerebrospinal fluid (CSF) markers for the diagnosis of Creutzfeldt-Jakob disease (CJD) 
include 14-3-3 protein, total tau protein (t-tau), neuron-specific enolase and S100B 
protein, and development of a new marker to detect the disease-associated form of prion 
protein (PrP) is ongoing.  T-tau levels in CSF (CSF-tau) are markedly elevated in patients 
with CJD [1].  Tau is produced mainly in the central nervous system (CNS), and some 
CSF-tau may leak into the blood [2].  We had a hypothesis that patients with CJD may 
show high levels of t-tau in serum (serum-tau) in association with marked elevation of 
CSF-tau levels.   
Previous studies have indicated that Alzheimer’s disease (AD) is the most frequent 
alternative diagnosis for CJD [3- 7].  Although, generally, there is little difficulty in 
making a differential diagnosis between CJD and AD, some atypical cases of CJD may 
present with slowly progressive clinical course mimicking AD [8].   Other neurologic 
diseases with rapidly progressive dementia (RPD), such as viral encephalitis and vascular 
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encephalopathy, may be indistinguishable from CJD, especially during the initial phase of 
the disease [9].   
Here we evaluated serum- as well as CSF-tau levels in patients with CJD, in 
comparison with those in patients with AD and patients who showed RPD mimicking 
CJD at the onset and later had diagnosis other than CJD (non-CJD-RPD). 
 
Methods 
We studied serum- and CSF-tau in CJD [median age ± SE (range), 73 ± 1.7 (65- 83) 
years] (n = 12), AD [71 ± 3.2 (53- 80) years] (n = 10), and non-CJD-RPD groups [59 ± 
4.2 (43- 76) years] (n = 9).   
The 12 patients with CJD were all sporadic cases, and were classified to 4 with 
definite (neuropathologically confirmed) CJD and 8 with probable CJD according to the 
World Health Organization (WHO) criteria [10].  None of these subjects had a family 
history of CJD or a history of receiving cadaveric dura mater grafts during neurosurgical 
procedures.  Analysis of the PrP gene revealed no mutation, and the polymorphic codons 
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showed methionine homozygosity at codon 129 and glutamic acid homozygosity at codon 
219 in all patients.  According to Parchi’s classification [11], the 4 definite cases were 
further classified to 3 with the MM2-cortical form characterized clinically by relatively 
slow progression of dementia, and 1 with the MM1 type characterized by a classic CJD 
phenotype showing RPD, myoclonus and positive periodic sharp-wave complexes.  The 8 
probable cases showed the classic CJD phenotype, probably classified to MM1 type.   
Patients with AD fulfilled the NINCDS-ADRDA criteria [12] for probable AD.  
General physical and neurologic examinations, neuropsychological evaluations, magnetic 
resonance imaging (MRI) of the brain and single photon emission computed tomography 
(SPECT) of cerebral blood flow (CBF) were conducted to confirm the accuracy of the 
clinical diagnosis.  The patients with AD showed medial temporal lobe atrophy on MRI 
and hypoperfusion in the posterior cinglate gyrus/precuneus or parieto-temporal lobe on 
CBF-SPECT, but no hyperintensity in the cortex or basal ganglia on diffusion-weighted 
MRI.  The levels of cognitive impairment were defined by a Clinical Dementia Rating 
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(CDR) scale [13-14], and the CDR score of each patient was 1.0.  All patients with AD 
were subjected to the Mini-Mental State Examination (MMSE) [22 ± 6.3 (20- 26)] [15].   
The non-CJD-RPD group included patients who had fulfilled the WHO criteria for 
‘possible’ CJD [10] at onset and had a final diagnosis other than CJD: viral encephalitis 
(n = 4), paraneoplastic syndrome (n = 2), hydrocephalus (n = 1), tuberculous meningitis 
(n = 1) and multiple cerebral infarction (n = 1).   
In addition, as a control group, we analyzed serum-tau in healthy volunteers [71 ± 0.8 
(66- 73) years] (n = 10).  All healthy volunteers underwent medical screening, including a 
questionnaire regarding medical history, general and neurological examinations and 
neuropsychological testing with the MMSE.  Those subjects with a history of head trauma, 
psychiatric or neurological disorders, uncontrolled major systemic diseases or an MMSE 
score of less than 28 were excluded.  All groups were matched for age, except the non-
CJD-RPD group in which ages were significantly younger than in CJD or healthy 
controls (p < 0.005 and p < 0.05, respectively).  There was no difference in the duration 
of illness between the CJD group [duration (range), 3 ± 1.6 (1- 18) months] and the non-
Noguchi-Shinohara et al. 8 
 
CJD-RPD group [3.5 ± 2.1 (0.3- 18) months], but the duration of illness in the AD group 
[18 ± 3.8 (11- 36) months] was significantly longer comparison with the CJD and non-
CJD-RPD groups (p < 0.0001 and p < 0.0005, respectively).   
Written informed consent was obtained from all participants or their caregivers.  The 
human subjects committee of our university hospital approved this study.   
Serum and CSF samples were collected on the day of diagnosis.  One of the patients 
with CJD had chronic hepatitis C and participated in a clinical trial before the onset of 
CJD.  His blood had been stored regularly for evaluation in clinical trials for two years.  
We obtained permission to use the blood samples for our study.   
Serum and CSF samples were centrifuged immediately after collection and stored at - 
80 °C until measurement in addition to a routine examination.  The CSF and serum 
samples were analyzed for t-tau and albumin.  A sandwich enzyme-linked 
immunosorbent assay (ELISA) was used to measure serum- and CSF-tau using the 
manufacturer’s instructions with some modification (Innotest hTAU-Ag; Innogenetics).  
Each ELISA plate was coated with anti-tau antibody AT120, as the capturing antibody.  
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After adding 75 L of anti-tau antibody HT-7 and BT-2, as detection antibodies, 25 L of 
the serum and CSF samples were applied to each well, and the plate was incubated 
overnight at 23ºC.  After washing with phosphate buffer, the wells were incubated with 
100 L/well of horseradish peroxidase (HRP)-labeled streptavidin for 30 min at 23ºC.  
Bound HRP activity was assayed using tetramethyl benzidine.  The HRP reaction was 
terminated with 2N sulfuric acid (100 µL/well), and absorbance at 450 nm was measured 
with a micro plate reader.  All samples and standards were run in duplicate on the same 
day with the same lot of standards.  The relative concentration estimates of serum- and 
CSF-tau were calculated according to the standard curve.  The standard curve was 
composed of 7 points (1200, 600, 300, 150, 75, 37.5 and 18.8 pg/mL) and dilutions were 
made with phosphate buffer.  The blank was phosphate buffer alone.  Ten determinations 
of the lowest standard (18.8 pg/mL) were significantly higher than 50 determinations of 
the blank (p<0.0001) for an absorbance of 450 nm.  Thus we determined the lowest 
detection limit to be 18.8 pg/mL.  Values below the detection limit were set to zero for 
further statistical analyses.  Quantitative determination of albumin in serum and CSF was 
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performed by nephelometry using standard methods.  The CSF/serum albumin ratio 
(albumin ratio) [16], [CSF-albumin (mg/L)/serum-albumin (g/L)], was calculated as a 
measure of the blood-brain barrier (BBB) function.  Further, the serum/CSF tau ratio (tau 
ratio), [serum-tau (pg/mL)/CSF-tau (pg/mL)], was calculated as a measure of leakage of 
t-tau from CSF to blood.  The groups were compared using an analysis of variance or the 
Kruskal-Wallis test according to the distribution of the data, and if applicable, with a post 
hoc analysis.  Correlations were evaluated by Spearman’s rank correlation test.  Values 
with p < 0.05 were regarded significant.  Statistical analyses were performed using SPSS 
version 12.0J for Windows (SPSS Inc., Chicago, IL, USA).   
 
RESULTS 
Serum-tau levels were significantly higher in the CJD group [median ± SE (range), 
193 ± 72.6 (35.0- 919.0) pg/mL] compared to those in the AD (p < 0.001) [0 ± 3.3 (0- 
33.3) pg/mL], non-CJD-RPD (p < 0.01) [22 ± 21.8 (0- 185.0) pg/mL] and healthy control 
(p = 0.001) groups [0 ± 9.37 (0- 89.0) pg/mL] (Fig. 1).  Serum-tau levels from 3 patients 
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with the MM2-cortical form of sporadic CJD [50 ± 137.4 (40.0- 457.0) pg/mL] tended to 
be higher than those in AD group patients (p = 0.0619) and healthy controls (p = 0.0767) 
but similar to those in the non-CJD-RPD group.  CSF-tau levels in the CJD group were 
significantly higher than those in the AD (p < 0.05) and non-CJD-RPD (p < 0.05) groups 
(Fig. 2).  The albumin ratio did not differ significantly between the CJD (median ± SE, 
7.6 ± 1.18), non-CJD-RPD (9.1 ± 2.83) and AD (5.7 ± 1.26) groups.  There was no 
difference in the tau ratio between the CJD group (median ± SE, 0.019 ± 0.04), non-CJD-
RPD group (0.024 ± 0.07) and AD group (0 ± 0.01).  There were no significant 
correlations between the albumin ratio and tau ratio in total or in any of the groups. 
Serum samples obtained before onset of CJD (12, 3, 2 and 1 month before onset) 
showed undetectable serum-tau levels.        
 
DISCUSSION 
Our results revealed that serum-tau as well as CSF-tau were significantly elevated in 
the CJD group compared to those in the AD, non-CJD-RPD, and control groups.  When 
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the CJD group was limited to the MM2-cortical form of sporadic CJD characterized by 
relatively slow progression of dementia, serum-tau levels tended to be higher than those 
in the AD or control groups.   
Microtubule-associated protein tau is localized in axons of the CNS neurons [17].  
Previous studies have reported that the concentration of serum-tau was elevated in 
patients with acute neurologic disorders, such as stroke, and it was below the detection 
limit in neurologically healthy participants [18-19].  Little is known about the passage of 
tau from the brain into the blood.  Disruption of BBB might be related to the leakage of 
tau from CSF to blood.  We could not have the albumin ratio for the control group, as we 
had no CSF samples for it.  The albumin ratio was reported to be 5.44 ± 2.16 (mean ± 
SD) in healthy individuals (n=231) in a previous study [19].  The albumin ratios in the 
CJD, AD, and non-CJD-RPD groups in this study were higher than those reported in 
healthy controls [19], which suggests some damage of BBB in CJD, AD, and non-CJD-
RPD.  Further, our results revealed no correlations between the albumin ratio and tau ratio 
in the CJD, AD or non-CJD-RPD groups, indicating that leakage of tau from CSF into the 
Noguchi-Shinohara et al. 13 
 
blood would not be simply associated with BBB disruption represented by the albumin 
ratio.   
Analysis of serial changes of serum-tau indicated that serum-tau levels would be 
elevated to be detectable after onset of CJD.  Regarding serial changes of CSF-tau levels, 
it was reported in a patient with CJD that CSF-tau level was relatively low at 2 months 
before disease onset, and then rose sharply at 6 weeks after onset [20].  The CSF-tau 
levels before disease onset reported in the previous study with CJD [20] appear consistent 
with those of serum-tau levels in our study.   
The serum-tau levels could be measured in all samples of the CJD group, on the other 
hand, they were below the detection limit in 4 of 9 samples of the non-CJD RPD group.  
We suggest that the possibility of CJD should be carefully examined if serum-tau was 
detectable in RPD.  Medical procedures such as neurosurgery and ophthalmic surgery 
before the diagnosis of CJD may be associated with risk of secondary transmission of 
CJD through contaminated instruments.  Our recent study revealed that 0.8% of patients 
with CJD underwent neurosurgery after the onset, but before the diagnosis of CJD, and 
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1.8% of patients with sporadic CJD ophthalmic surgery [21].  Measurement of serum-tau 
before neurosurgery and ophthalmic surgery in patients with dementia may be a simple 
and useful tool for the screening of CJD.  
The limitations of this study were the small sample size.  Only 4 cases with 
neuropathologically confirmed CJD were available.  Probably due to very high proportion 
of MM genotype at PrP codon 129 in the Japanese population  (93%) [22], all the 12 
patients with sporadic CJD in this study had MM genotype at codon 129, including 3 with 
the MM2-cortical form; the MM2-type sporadic CJD is common among atypical CJD 
cases in Japan [22].  While, no patients with VV or MV genotype, rare genotypes in 
Japan [22], could be included in this study, although VV2-type sporadic CJD is the 
second commonest form in European countries and the USA [11][23].  In addition, to 
reveal the statistical significance in serum-tau levels for the MM2-cortical form of 
sporadic CJD, further study with a larger number of the patients is necessary.   
In conclusion, serum-tau would be a simple and useful marker to distinguish CJD 
from AD and non-CJD-RPD, requiring further large study to confirm this.   
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Serum levels of total tau protein (serum-tau) in sporadic Creutzfeldt-Jakob disease (CJD), 
Alzheimer’s disease (AD), patients with rapidly progressive dementias but no CJD (non-
CJD-RPD) and healthy control groups.   
The black circles plotted with a sharp (●#) indicate patients with the MM2-cortical form 
of sporadic CJD.  Values below the detection limit were set to zero.  Serum-tau in CJD 
group patients was significantly different from that in AD group patients (*p < 0.001), 
healthy controls (**p = 0.001) and non-CJD-RPD group patients (***p < 0.01).   
 
Fig. 2 
Cerebrospinal fluid (CSF) levels of tau (CSF-tau) in sporadic CJD, AD and non-CJD-
RPD groups.  The black circles plotted with a sharp (●#) indicate patients with the MM2-
cortical form of sporadic CJD.  Values below the detection limit were set to zero.  CSF-
tau in the CJD group [median ± SE (range): 4538 ± 5599.4 (693- 69680) pg/mL] were 
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significantly different from those in AD [790.5 ± 174.1 (210- 1743) pg/mL; ****p < 
0.05] and non-CJD-RPD groups [496 ± 250.5 (70- 2400) pg/mL; ****p < 0.05] 
 


